EU Commission to better define medtech directive scope: borderline and aesthetic issues
This article was originally published in Clinica
Executive Summary
One of the European Commission’s key aims in the recast of the medical device directives is to ensure that there is much greater clarity about which products are regulated under the directives and which product areas do not come under their scope. Areas focus include products on the borderline with other directives, as well as implantables or other invasive devices without a medical purpose.
You may also be interested in...
EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency
Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.
First Public Discussion On How EU Medtech Regulatory Governance Structure May Evolve
Does the EU need a medtech agency for the first time in its history? Nothing can or should be decided too quickly but five high-profile experts broadly agreed that change is now critical.
First Danish Notified Body Named Under EU's Medical Device Regulation
The EU now has a total of 45 notified bodies under the MDR.